AFT Pharmaceuticals Ltd. 2021 AR2
The report highlights AFT Pharmaceuticals' operational and financial performance for the fiscal year ended March 31, 2021, achieving a record revenue of $113.1 million despite global disruptions from the COVID-19 pandemic. The company made significant progress in commercializing its Maxigesic pain relief family, including licensing Maxigesic IV in the US with Hikma Pharmaceuticals. AFT also advanced its sustainability efforts by benchmarking its ESG performance, joining the Australian Packaging Covenant Organisation (APCO) to improve packaging sustainability, and actively promoting workforce diversity with 61% female employees. Additionally, the company adapted to pandemic challenges by implementing remote manufacturing audits and prioritizing employee health and safety.
Company: AFT Pharmaceuticals Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2021
Type: AR2
Pages: 44
Back to company
AFT Pharmaceuticals Ltd.
Annual Report
The report highlights AFT Pharmaceuticals' operational and financial performance for the fiscal year ended March 31, 2021, achieving a record revenue of $113.1 million despite global disruptions from the COVID-19 pandemic. The company made significant progress in commercializing its Maxigesic pain relief family, including licensing Maxigesic IV in the US with Hikma Pharmaceuticals. AFT also advanced its sustainability efforts by benchmarking its ESG performance, joining the Australian Packaging Covenant Organisation (APCO) to improve packaging sustainability, and actively promoting workforce diversity with 61% female employees. Additionally, the company adapted to pandemic challenges by implementing remote manufacturing audits and prioritizing employee health and safety.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees